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Background: Varenicline is probably the most effective smoking cessation pharmacotherapy, but is less widely
used than nicotine replacement therapy. We therefore set out to identify the characteristics of numerically
important groups of patients who typically do, or do not, receive varenicline in the UK.
Methods: We used association rule mining to analyse data on prescribing of smoking cessation pharmacotherapy
in relation to age, sex, comorbidity and other variables from 477,620 people aged 16 years and over, registered as
patients throughout 2011 with one of 559 UK general practices in The Health Improvement Network (THIN)
database, and recorded to be current smokers.
Results: 46,685 participants (9.8% of all current smokers) were prescribed any smoking cessation treatment during
2011, and 19,316 of these (4% of current smokers, 41% of those who received any therapy) were prescribed
varenicline. Prescription of varenicline was most common among heavy smokers aged 31–60, and in those with a
diagnosis of COPD. Varenicline was rarely used among smokers who were otherwise in good health, or were aged
over 60, were lighter smokers, or had psychotic disorders or dementia.
Conclusions: Varenicline is being underused in healthy smokers, or in older smokers, and in those with psychotic
disorders or dementia. Since varenicline is probably the most effective available single cessation therapy, this study
identifies under-treatment of substantial public health significance.
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Smoking is the largest avoidable cause of death in the
UK. About half of all life-long smokers will die prema-
turely, losing on average about 10 years of life [1,2].
There were a total of 442,759 deaths of adults aged 35
and over in England of which 79,100 (18%) were esti-
mated to be attributable to smoking in 2011 [3].
Smoking cessation treatments are one of the most cost
effective of all health care treatments. Of available phar-
macotherapies, NRT and varenicline are most widely used.
Varenicline is a competitive nicotine receptor antagonist
with partial agonist activity that has been available as a
smoking cessation treatment since 2006. Its targeted* Correspondence: yue.huang@nottingham.ac.uk
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unless otherwise stated.mechanism of action, better efficacy and tolerability makes
varenicline a useful therapeutic option for smoking cessa-
tion [4]. Varenicline therapy increases the likelihood of
sustained cessation relative to placebo by a ratio of around
2.3, and may be more effective than conventional Nicotine
Replacement Therapy (NRT) [5]. However, whilst use of
varenicline has been approved by NICE since 2008 [6], it
has not been as widely used as NRT [7]. Available clinical-
trial data [8] has supported varenicline as a first-line treat-
ment option for smoking cessation in healthy adult
smokers, but to our knowledge, the use of it in the general
population, particularly those with comorbid conditions
has not been reported.
We have previously used data mining methods in a large
nationally representative primary care database to demon-
strate that there are identifiable groups of patients who
are systematically failing to be offered any treatment forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The description of the study population
Total Receiving varenicline
n % n %
Total 477620 19316 4.04
Age groups, years
16-30 126382 26.5 3593 2.84
31-45 139778 29.3 7004 5.01
46-60 125127 26.2 6118 4.89
>60 86333 18.1 2601 3.01
Sex
Male 237709 50.0 7861 3.57
Female 239911 50.0 8730 4.05
Lifestyle
Alcohol 15132 3.2 457 3.02
Heavy smoker 56619 11.9 4564 8.06
Obesity 45805 9.6 1901 4.15
Medical condition
Asthma 71759 15.0 3494 4.87
Atrial fibrillation 4629 1.0 105 2.27
Cancer 10862 2.3 457 4.21
CHD 17271 3.6 706 4.09
CKD 12313 2.6 307 2.49
COPD 22227 4.7 1511 6.80
Dementia 4198 0.9 79 1.88
Depression/anxiety 144520 30.3 6202 4.29
Diabetes 22817 4.8 931 4.08
Epilepsy 5433 1.1 108 1.99
Heart failure 3452 0.7 78 2.26
Hypertension 59505 12.5 2054 3.45
Learning disability 1239 0.3 15 1.21
Psychotic disorders 7544 1.6 81 1.07
Stroke or TIA 10979 2.3 430 3.92
Thyroid 19394 4.1 818 4.22
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smokers and those with dementia or hypertension [9]. We
have now used the same methods to investigate the charac-
teristics of smokers who do and do not receive prescriptions
for varenicline, using data from a nationally representative
primary care database for 2011.
Methods
Study population
We used data from The Health Improvement Network
(THIN), a large electronic anonymised primary care
database, with records from 559 general practices across
the UK. We identified for analysis all individuals aged
16 years or over who had been registered with a THIN
practice throughout 2011, and whose record indicated
that they were a current smoker, either having a Read
code indicative of current smoking recorded during
2011, or in those with no smoking status recorded in
2011, since 1st Oct 2009. Since the Quality and Outcomes
Framework (QOF) requires general practitioners (GPs) to
record the smoking status of their patients at least every
27 months, all individuals should have had a smoking sta-
tus recorded in this timeframe [10].
For each of these patients, we identified whether they
had received a prescription for varenicline during 2011,
using drug codes from BNF. We also extracted data on
age (categorised as 16 to 30, 31 to 45, 46 to 60 and 61 or
over), gender, whether patients were coded as heavy
smokers (>20 cigarettes/day), had alcohol weekly con-
sumption over recommended levels (>14 units/week for
women and 21 units/week for men) and obesity (body
mass index >30). We extracted data on medical conditions
based on the clinical disease indicators in the Quality and
Outcomes Framework (QOF), including asthma, atrial fib-
rillation, cancer, coronary heart disease (CHD), chronic
kidney disease (CKD), chronic obstructive pulmonary dis-
ease (COPD), dementia, anxiety or depression, diabetes,
epilepsy, heart failure, hypertension, learning disability,
psychotic disorders, stroke or transient ischaemic attack
(TIA) and thyroid disorders. Any diagnosis made before
the end of 2011 was included.
Ethics statement
Ethical approval for the use of THIN data for this study
was obtained from the THIN Scientific Review Committee
(reference number 10–022A).
Analysis
We used association rule mining (ARM) to discover the
combined characteristics of groups of patients who did,
or did not receive a varenicline prescription. ARM is one
of the most well-established techniques in data mining,
and has been widely applied in many areas. ARM identi-
fies rules of the form A = > B, where A is the subset ofexposures, and B is the subset of outcomes. A and B are
mutually exclusive. We used the ARM method to iden-
tify rules for sets of characteristics (A) of patients who
did, and did not, receive a prescription for varenicline
during 2011 (B), carrying out two separate analyses for
these two different outcomes (receiving varenicline/
NOT receiving varenicline). ARM rules are produced to
meet minimum constraints on level of ‘support’ for the
rule, that is, the proportion or number of the study
population, in this case current smokers, with the char-
acteristics in set A. Since we were interested in identify-
ing numerically important exposure groups while also
ensuring that each of the patient groups represented by
the disease indicators had potential to be included in
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to ensure that exposure groups were numerically im-
portant. The rules were listed in order of ‘confidence’ ,
that is the probability of B given A, or the probability of
receiving, or not receiving, a prescription given that the
patient has each of the characteristics in the set A. A
more detailed description of our ARM approach was
provided in our previous study which investigated the
characteristics of smokers who received any smoking
cessation prescription in primary care [9]. We used the
open-source data mining software WEKA [11] to under-
take the ARM analyses.
Results
A total of 477,620 smokers were identified and included
in the analysis. Of these, 46,685 (9.8%) received a prescrip-
tion for one or more smoking cessation medication during
2011, and 19,316, 4.0% of all smokers, were prescribed
varenicline (Table 1).Table 2 Top 10 generated rules for smokers prescribed varen
size > =500)




alcohol = NO, heavy smoker = YES, obesity = NO,
dementia = NO, depression/anxiety = NO, epilepsy = NO,
hypertension = NO, psychotic disorders = NO, age = 31-
45, gender = female
14.9
1.2
alcohol = NO, heavy smoker = YES, obesity = NO,
depression/anxiety = NO, epilepsy = NO, hypertension =NO,
psychotic disorders = NO, age = 31-45, gender = female
14.8
1.3
alcohol = NO, heavy smoker = YES, obesity = NO,
dementia = NO, depression/anxiety = NO, epilepsy = NO,
hypertension = NO, psychotic disorders = NO, age = 31-45
14.0
1.4
alcohol = NO, heavy smoker = YES, obesity = NO,
depression/anxiety = NO, epilepsy = NO, hypertension =NO,
psychotic disorders = NO, age = 31-45
14.0
1.5
alcohol = NO, heavy smoker = YES, obesity = NO,
dementia = NO, depression/anxiety = NO, hypertension
= NO, psychotic disorders = NO, age = 31-45
13.9
1.6
alcohol = NO, heavy smoker = YES, obesity = NO,
depression/anxiety = NO, hypertension = NO, psychotic
disorders = NO, age = 31-45
13.8
1.7
alcohol = NO, heavy smoker = YES, obesity = NO,
dementia = NO, depression/anxiety = NO, epilepsy = NO,




alcohol = NO, heavy smoker = YES, obesity = NO,
depression/anxiety = NO, epilepsy = NO, hypertension =NO,
psychotic disorders = NO, age = 31-45, gender =male
13.4
1.9
alcohol = NO, heavy smoker = YES, obesity = NO, asthma
= YES, CKD = 0, COPD = YES, dementia = NO, epilepsy =
NO, hypertension = NO, learning disability = NO,
psychotic disorders = NO, age = 46-60
13.4
1.10
alcohol =NO, heavy smoker = YES, obesity =NO, COPD=
YES, dementia =NO, depression/anxiety =NO, epilepsy =NO,
hypertension =NO, psychotic disorders =NO, age = 46-60
13.3The patients identified by the top 10 rules (Table 2) for
receiving a varenicline prescription were all heavy smokers
aged between 31 and 60 who were not heavy drinkers, were
not obese and did not have hypertension. Some also had
COPD (rules 1.9 and 1.10). They did not have mental
health problems including anxiety or depression, psychotic
disorders and dementia; and did not have epilepsy. In these
groups of patients, confidence was 13.3% or more, so the
proportions receiving a varenicline prescription was much
higher than the 4% in the general population of smokers.
When we applied the same approach to identify those
who did not receive varenicline, we initially generated a
large number of rules of the form ‘one or more disease/
lifestyle indicator =NO’, and their confidence levels were
all very high (>97%, most of them 100%), indicating that
non-heavy smokers in good health are very unlikely to re-
ceive varenicline. To explore prescribing in those with
other co-morbidity, therefore we reset the constraints for
rule generation such that our disease indicators wereicline & NOT prescribed varenicline (exposure group
Outcome = NOT prescribed varenicline
(Analysis 2)
(%) Exposure2 Confidence (%)
2.1
psychotic disorders = YES,
age > 60, sex = female
99.7
2.2
COPD = NO, psychotic




alcohol = YES, psychotic
disorders = YES 99.6
2.4
psychotic disorders = YES,
age > 60 99.5
2.5
heavy smoker = NO, COPD = NO,
dementia = YES, age > 60 99.5
2.6
heavy smoker = NO, psychotic
disorders = YES, age > 60 99.4
2.7
COPD = NO, psychotic
disorders = YES, age > 60
99.4
2.8
heavy smoker = NO,




heavy smoker = NO, COPD = NO,
psychotic disorders = YES, age > 60
99.3
2.10
heavy smoker = NO, psychotic
disorders = YES, age = 31-45,
gender = male
99.3
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10 rules for smokers who did not receive a varenicline
prescription are also shown in Table 2 (analysis 2). In
these smokers, 8 out of 10 rules define groups of patients
with psychotic disorders, and the other 2 defined groups
with dementia. Most of the groups defined by these rules
were patients aged over 60 who were not heavy smokers
and/or did not have COPD. These were groups in which
confidence was 99.3% or more, so that 0.7% or less were
receiving a prescription.
Discussion
To our knowledge, this is the first study to investigate the
prescribing of varenicline for smoking cessation treatment
in UK general practice. The advantage of using the ARM
method is that it allows us to approach data with no prior
hypothesis or null hypothesis, and to identify the combi-
nations of characteristics that define those who are espe-
cially likely or unlikely to get a prescription. Our study
demonstrates that only about one in every 25 current
smokers ascertained by general practitioners were pre-
scribed varenicline during the one year study period, while
ARM analysis demonstrates that varenicline was pre-
scribed preferentially to heavy smokers who were other-
wise healthy, or who had COPD. The most notable groups
who were not prescribed varenicline were those who were
older, and those with mental health conditions, particu-
larly psychotic disorders or dementia. Varenicline was also
less likely to be prescribed in lighter smokers, and in
people with epilepsy, atrial fibrillation or hypertension.
People with severe mental health problems are more
likely to smoke and to smoke more heavily, are less
likely to quit smoking, and experience a very high risk of
death or morbidity due to smoking [12]. However this
group is generally under-treated for smoking cessation
in primary care given their consultation rate [2]. The lat-
est study shows patients with mental health problems
can benefit from stopping smoking [13], and health pro-
fessionals have been encouraged to provide their patients
with the same level of smoking cessation support that is
given to the rest of the population [14-16]. Use of vare-
nicline has been inhibited by concerns over adverse
events, particularly depression and suicidal ideation
[5,17,18], with the result that this treatment may be
withheld from smokers perceived to be at particular risk
of these effects, such as those with existing mental
health problems. However, recent evidence suggests that
these concerns are unfounded [19], and both the BNF
and National Institute for Health and Care Excellence
(NICE) guidance indicate that the risk should be man-
aged by clinical monitoring, not by non-use [6,16,18].
Since continued smoking carries a more substantial
health risk for the great majority of these individuals,
this practice may be counterproductive to individual andpublic health. In recent trials, varenicline has been
shown to increase smoking cessation in smokers with
severe mental health problems without worsening their
mental health condition, and help to reduce the high
prevalence of tobacco dependence and the heavy burden
of smoking-related morbidity and mortality within this
population [20,21].
Smoking is also a risk factor for dementia [22] and smok-
ing cessation is recommended in secondary prevention of
the condition [15]. Our findings suggest that people with
dementia are very unlikely to receive varenicline, one of the
most effective cessation therapies, from their GP. Any risks
of adverse effects with smoking cessation therapies must be
balanced against the risk of continued smoking, which for
most users is the likely long-term untreated outcome.
Conclusion
In general, the message from ARM indicates that healthy
individuals are more likely to receive varenicline; on the
contrary, those smokers with more co-morbidity are less
likely to get varenicline. The balance of risks between
long-term sustained smoking and short term adverse ef-
fects of varenicline therapy suggests however that more
widespread use of varenicline could deliver substantial
individual and population health benefits. There is a case
for wider use of varenicline in the smoking population.
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